NRSN
NeuroSense Therapeutics Ltd. [NRSN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRSN Stock Summary
Top 10 Correlated ETFs
NRSN
Top 10 Correlated Stocks
NRSN
In the News
NRSN Financial details
Company Rating
-
Market Cap
21.87M
Income
-11.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
25 May 2024
P/E
-0.92
Forward P/E
-
PEG
0.65
P/S
-
P/B
-52.53
P/C
-
P/FCF
-
Quick Ratio
1.8
Current Ratio
1.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.83
EPS next Y
-
EPS next Q
-
EPS this Y
-14.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-430.43%
-
-
-
-
SMA20
78.07%
SMA50
103%
SMA100
87.96%
Inst Own
-
Inst Trans
-
ROA
-209%
ROE
-665%
ROC
-5.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-2.33
52W High
-
52W Low
-
RSI
79.9
Rel Volume
1.21
Avg Volume
314.29K
Volume
381.45K
Perf Week
40%
Perf Month
128.85%
Perf Quarter
108.77%
Perf Half Y
161.48%
-
-
-
-
Beta
1.56
-
-
Volatility
0.29%, 0.41%
Prev Close
0%
Price
2.38
Change
-4.03%
Company Profile
- Volume Average 314.29K
- Market Capitalization 21.87M
- Employee 18
- CEO Ms. Hagit Binder
- Headquarters Herzliya,IL
- IPO Date 2021-12-09
-
Website
https://www.neurosense-tx.com 
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
